Aclarion, Inc. (ACON)
NASDAQ: ACON · Real-Time Price · USD
3.380
+0.010 (0.30%)
At close: Apr 28, 2026, 4:00 PM EDT
3.370
-0.010 (-0.30%)
After-hours: Apr 28, 2026, 4:00 PM EDT

Company Description

Aclarion, Inc. operates as a healthcare technology company in the United States.

It uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments.

The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine.

It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform.

In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient.

The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021.

Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Aclarion, Inc.
Aclarion logo
Country United States
Founded 2008
IPO Date Apr 22, 2022
Industry Health Information Services
Sector Healthcare
Employees 6
CEO Brent Ness

Contact Details

Address:
8181 Arista Place, Suite 100
Broomfield, Colorado 80021
United States
Phone 833 275 2266
Website aclarion.com

Stock Details

Ticker Symbol ACON
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $4.35
CIK Code 0001635077
CUSIP Number 655187409
ISIN Number US6551874091
Employer ID 47-3324725
SIC Code 8071

Key Executives

Name Position
Brent Ness Chief Executive Officer, President and Director
Dr. Jeffrey John Thramann M.D. Executive Chairman
Gregory A. Gould CPA Chief Financial Officer
Ryan Bond Chief Strategy Officer

Latest SEC Filings

Date Type Title
Apr 27, 2026 DEF 14A Other definitive proxy statements
Apr 22, 2026 8-K Current Report
Apr 3, 2026 PRE 14A Other preliminary proxy statements
Mar 25, 2026 SCHEDULE 13G Filing
Mar 19, 2026 8-K Current Report
Mar 19, 2026 8-A12B Registration of securities
Mar 18, 2026 10-K Annual Report
Jan 13, 2026 8-K Current Report
Jan 9, 2026 8-K Current Report
Jan 9, 2026 424B5 Filing